Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.

International journal of cancer - 20 Jan 2000

Pfister C, Larue H, Moore L, Lacombe L, Veilleux C, Tetu B, Meyer F, Fradet Y

Abstract excerpt

Our aim was to determine whether the pattern of expression of the interrelated proteins p53, MDM2 and p21 could shed light on the etiopathogenic mechanisms of superficial bladder tumors. Protein expression was detected by immunohistochemistry (IHC) using monoclonal antibodies (MAbs) Pab 1801 for p53, IF2 for MDM2 and EA10 for p21 on 269 newly diagnosed bladder tumors (214 pTa and 55 pT1; 93 grade I, 145 grade 2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin-Dependent Kinase Inhibitor p21
Share to Cyclins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasm Proteins

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins c-mdm2

Share to Tumor Suppressor Protein p53

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 10719738

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.PMID 10719738Read ↗

Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.Semantic proximity Read ↗

Molecular pathogenesis of bladder cancer.Semantic proximity Read ↗

Prognostic implications of p53 gene mutations in bladder tumors.Semantic proximity Read ↗

Altered patterns of MDM2 and TP53 expression in human bladder cancer.Semantic proximity Read ↗

The p53 Pathway and Outcome among Patients with T1G3 Bladder TumorsSemantic proximity Read ↗

Mutation Of p53 And Its Clinical Significance In Muscle-Invasive Bladder TumorSemantic proximity Read ↗

The Emerging Molecular Landscape of Urothelial Carcinoma.Semantic proximity Read ↗

Genetic alterations in urothelial bladder carcinoma: an updated review.Semantic proximity Read ↗

Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.Semantic proximity Read ↗

Morphologic and Molecular Characteristics of Bladder Cancer.Semantic proximity Read ↗

The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.Semantic proximity Read ↗

FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.